Oral sessions summaries
Alopecia Areata
View
Initial results from a long-term, open-label extension study with CTP-543, an oral janus kinase inhibitor, in patients with moderate to severe alopecia areata
EADV Virtual - Oral session
Atopic Dermatitis
View
Safety and Efficacy of Upadacitinib Monotherapy in Adolescents and Adults with Moderate-to-severe Atopic Dermatitis: Results From 2 Pivotal, Phase 3, Randomized, Double-blinded, Monotherapy, Placebo-controlled Studies (Measure Up 1 and Measure Up 2)
EADV Virtual - Oral session
COVID-19
View
Use of biologics and immunosuppressive drugs in COVID period
EADV Virtual - Oral session
Epidermolysis Bullosa
View
Efficacy and safety of oleogel-S10 for epidermolysis bullosa – Results of 3 months double-blind treatment during the phase 3 study EASE
EADV Virtual - Oral session
Hidradenitis Suppurativa
View
Biologics in the management of hidradenitis suppurativa
EADV Virtual - Oral session
-
DOWNLOAD
THE APP